One year after its June 2025 launch, Neuro Space (脑智天地) — Shanghai's BCI industry cluster at the Hongqiao International Medical Center and China's first dedicated BCI industrial zone — has entered full operation across its 25,000 m² pilot area. As of July 2026, the cluster hosts 52 registered BCI companies and 22 startup incubators spanning flexible electrodes, BCI chips, ultrasound-based interfaces, and vision restoration.
On the commercialization front, the world's first approved invasive BCI medical device, developed in Shanghai, received regulatory clearance in 2026, with its first clinical prescription issued in July. Five additional Class III devices are currently in clinical trials or under regulatory review. Shanghai accounts for nearly 60% of China's BCI financing events, totaling approximately RMB 2.117 billion.
Products showcased at a recent open-day event include a non-invasive brain-controlled consumer device driven by EEG-based attention metrics, an integrated transcranial magnetic stimulation navigation system for depression treatment, and LingXi Cloud, a clinical data platform housing over 2.1 million cases of multimodal brain-disorder data at petabyte scale.
